Estonian medtech firm Nanordica Medical has successfully secured €1.6 million in a recent funding round. The investment, led by 2C Ventures, is earmarked for the commercialisation of its advanced antibacterial wound dressing, Premotiv®. This capital will accelerate the technology's entry into the European market to address the needs of patients with chronic wounds.
Addressing a Critical Healthcare Challenge
Chronic wounds represent a significant global health issue, affecting approximately 100 million people worldwide. Over half of these wounds become infected, leading to severe outcomes such as sepsis, amputation, and even death. Diabetic foot ulcers are a primary cause of these complications and remain a leading reason for lower-limb amputations.
A Novel Approach to Wound Care
Nanordica Medical is tackling this problem with its patent-protected Premotiv® technology, designed to both prevent infection and promote healing. This innovative dressing overcomes the common trade-off between antimicrobial effectiveness and safety for healthy skin cells. The technology offers a solution for infected wounds and those at high risk of infection without compromising the natural healing process.
Strong Clinical Validation
The efficacy of Premotiv® is supported by compelling clinical data from an initial randomised controlled trial. The study, published in the Journal of Wound Care, showed a 43% reduction in wound area after one week. This result significantly outperformed standard silver dressings, which achieved only a 13% reduction in the same period.
To build on these findings, the company is conducting a larger multicentre trial involving more than 120 patients. This extensive study is designed to generate robust evidence required for reimbursement approvals and inclusion in future treatment guidelines. The results are expected to facilitate broader clinical adoption of the advanced wound care technology across healthcare systems.
Strategic Funding for Market Entry
Martin Koppel, Founding Partner at lead investor 2C Ventures, highlighted the technology's importance in combating antimicrobial resistance. He praised Nanordica for developing a clinically proven alternative that does not rely on antibiotics or compromise healing. Koppel noted the team's scientific expertise and conviction as key factors in their investment decision.
The company has already achieved key milestones, including ISO 13485 certification and the launch of a veterinary product. This new funding will enable the completion of the large clinical study and finalise the CE marking process. These steps are crucial for the commercial launch of Premotiv® for human use throughout Europe.
This €1.6 million investment marks a pivotal moment for Nanordica Medical as it prepares to enter the European market. CEO Olesja Bondarenko stated the funding will strengthen the economic case for Premotiv® and improve outcomes for patients. With its clinically validated technology, the company is well-positioned to offer a new standard of care for chronic wounds.